Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

249
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
249
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

224
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
224
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

356
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
356

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Switching Biologics in Severe Asthma: Cautionary Lessons from NIMBLE.

American journal of respiratory and critical care medicine·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

Anaphylaxis and Epinephrine Use in Pregnancy.

The journal of allergy and clinical immunology. In practice·2026
Same author

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

The Lancet. Respiratory medicine·2026
Same author

Use of an Anti-Thymic Stromal Lymphopoietin Agent in Patients With Asthma and Clinically Significant Bronchiectasis: A Case Series.

Chest·2026
Same author

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors.

Allergy·2026
Same journal

Real-time algorithm-driven ventilation feedback to improve lung-protective ventilation in patients with ARDS (REALVENT-study): study protocol for a multicentre randomised controlled trial.

Respiratory research·2026
Same journal

Identification and functional validation of lactylation-related hub genes in idiopathic pulmonary fibrosis based on multi-omics analysis.

Respiratory research·2026
Same journal

NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.

Respiratory research·2026
Same journal

Direct visualisation and measurement of lung microstructure reveal insights into extracellular matrix dysregulation in COPD.

Respiratory research·2026
Same journal

Proteo-metabolomic insights into the progression of chronic obstructive pulmonary disease and lung function decline.

Respiratory research·2026
Same journal

Lung ultrasound feature tracking to quantify regional lung strain in mechanically ventilated pigs.

Respiratory research·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles.

Marco Caminati1,2, A Vatrella3, P Rogliani4

  • 1Allergy Unit and Asthma Center, Integrated University Hospital of Verona, Verona, Italy. marco.caminati@univr.it.

Respiratory Research
|October 9, 2024
PubMed
Summary
This summary is machine-generated.

Tezepelumab effectively treats asthma by targeting epithelial dysfunction, identifying best-fit patients through functional biomarkers like airway hyperreactivity. This approach refines personalized medicine beyond traditional asthma phenotypes.

Keywords:
BiomarkersEpithelial barrierPhenotypingSevere asthmaTezepelumab

More Related Videos

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

678
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.6K

Related Experiment Videos

Last Updated: Jun 11, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

678
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.6K

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Epithelial Biology

Background:

  • Epithelial dysfunction is increasingly recognized in asthma pathogenesis.
  • Tezepelumab, a TSLP-targeting biologic, shows broad efficacy in asthma patients.
  • Identifying specific patient profiles is crucial for optimizing tezepelumab use.

Purpose of the Study:

  • To define the optimal patient profile for tezepelumab treatment.
  • To identify hallmarks of epithelial-driven asthma.
  • To review evidence on tezepelumab's mechanism and efficacy.

Main Methods:

  • Review of published data on tezepelumab's mechanism of action and clinical efficacy.
  • Analysis of potential biomarkers associated with epithelial barrier dysfunction.
  • Correlation of environmental exposures with asthma exacerbations and treatment response.

Main Results:

  • Epithelial barrier dysfunction is linked to environmental exposures, infections, and exacerbations.
  • Tezepelumab reduces exacerbations triggered by allergens and respiratory illnesses.
  • Functional biomarkers like airway hyperreactivity and bronchial reversibility indicate tezepelumab response.

Conclusions:

  • Functional biomarkers, alongside inflammatory markers, enable a more comprehensive asthma phenotyping.
  • This approach moves beyond restrictive labels like T2-high or T2-low asthma.
  • Precise phenotyping optimizes personalized medicine for tezepelumab-eligible patients.